(R)-4-Methyloxazolidin-2-one → (R)-3-{5-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-2-yl}-4-methyloxazolidin-2-one

HRID 1803969

반응식

HRID 1803969 반응식
Br[C:2]1[N:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([C:16](=[O:24])[C:17]3[CH:22]=[CH:21][C:20]([Cl:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[CH3:25][C@@H:26]1[CH2:30][O:29][C:28](=[O:31])[NH:27]1>>[Cl:23][C:20]1[CH:21]=[CH:22][C:17]([C:16]([CH:13]2[CH2:14][CH2:15][N:10]([C:8]([C:5]3[CH:4]=[CH:3][C:2]([N:27]4[C@H:26]([CH3:25])[CH2:30][O:29][C:28]4=[O:31])=[N:7][CH:6]=3)=[O:9])[CH2:11][CH2:12]2)=[O:24])=[CH:18][CH:19]=1

참가 물질

3

반응물 2

HCID 2734858(R)-4-Methyloxazolidin-2-oneHCID 58484839(6-Bromopyridin-3-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone

생성물 1

HCID 54755117(R)-3-{5-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-2-yl}-4-methyloxazolidin-2-one수율 41.8%

실험 절차

By reaction and treatment in the same manner as in Preparation Example 31 and using (6-bromopyridin-3-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone (2 g) described in Preparation Example 23 and (R)-4-methyloxazolidin-2-one (288 mg) described in Preparation Example 25, the title compound (510 mg) was obtained.

후처리

  1. customBy reaction and treatment in the same manner
  2. customas in Preparation Example 31
  3. customdescribed in Preparation Example 25

출처 및 근거

ORD 기록
ord-d93e8706497c4c05b6903add2c842b7b
출처 데이터셋
uspto-grants-2013_01
특허 번호
US08354401B2

연결된 노트

불러오는 중…